Amylyx stock soars after its GLP-1 blocker cut dangerous low-blood-sugar events in trial
Patients on avexitide experienced 55% fewer severe hypoglycemic events than those on a placebo in the late-stage study
We haven't written up this one. Quartz has the full story — the link below goes straight to it.